Shots: The P-II/II DIAN-TU-001 study involve assessing of Roche’s gantenerumab and Eli Lilly’s solanezumab vs PBO in 194 patients with ADAD for up to 7yrs. across 24 sites including the […]readmore
Tags : Autosomal Dominant Alzheimer’s Disease